Dyne Competitors
| DYN Stock | USD 16.80 0.25 1.51% |
Dyne Therapeutics vs CG Oncology Correlation
Excellent diversification
The correlation between Dyne Therapeutics and CGON is -0.57 (i.e., Excellent diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Dyne Therapeutics and CGON in the same portfolio, assuming nothing else is changed.
Moving together with Dyne Stock
Moving against Dyne Stock
| 0.57 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.5 | ENGN | enGene Holdings Common | PairCorr |
| 0.36 | DSGN | Design Therapeutics | PairCorr |
| 0.36 | 63E | ONWARD MEDICAL BV | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dyne Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dyne Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dyne Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Dyne and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dyne Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Dyne Stock performing well and Dyne Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dyne Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RARE | 3.02 | (0.35) | 0.00 | (0.13) | 0.00 | 7.73 | 51.23 | |||
| SLNO | 3.13 | (0.67) | 0.00 | (0.50) | 0.00 | 5.40 | 26.59 | |||
| CNTA | 2.27 | (0.01) | (0.02) | 0.06 | 2.71 | 4.97 | 26.54 | |||
| XENE | 1.65 | (0.01) | (0.03) | 0.05 | 1.97 | 3.78 | 10.56 | |||
| APGE | 2.10 | 0.15 | 0.05 | 0.20 | 2.82 | 4.56 | 23.21 | |||
| AAPG | 2.53 | (0.48) | 0.00 | (1.95) | 0.00 | 5.25 | 16.72 | |||
| MIRM | 2.01 | 0.51 | 0.21 | 0.90 | 1.95 | 4.60 | 16.13 | |||
| CELC | 2.29 | 0.51 | 0.21 | 0.89 | 2.04 | 5.87 | 17.89 | |||
| TLX | 2.25 | (0.62) | 0.00 | (0.54) | 0.00 | 4.24 | 15.35 | |||
| CGON | 3.02 | 0.30 | 0.10 | 0.40 | 2.73 | 5.15 | 34.61 |
Cross Equities Net Income Analysis
Compare Dyne Therapeutics and related stocks such as Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | (6.8 M) | (6.8 M) | (16.3 M) | (35.1 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (486.7 M) |
| SLNO | (6.5 M) | (6.5 M) | (6.5 M) | (3.7 M) | (13.9 M) | (15.9 M) | (12.1 M) | (15.7 M) | (13.3 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (39 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| CNTA | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (10.7 M) | (381.9 M) | (216.2 M) | (151.1 M) | (235.8 M) | (212.2 M) | (222.8 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| MIRM | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (163.4 M) | (87.9 M) | (79.1 M) | (83.1 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| TLX | (289 K) | (2.5 M) | (2.5 M) | (2.5 M) | 5.4 M | (132 K) | (44 K) | (6.4 M) | (13.8 M) | (27.9 M) | (44.9 M) | (80.5 M) | (104.1 M) | 5.2 M | 49.9 M | 44.9 M | 47.2 M |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
Dyne Therapeutics and related stocks such as Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Dyne Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dyne Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dyne Therapeutics Competitive Analysis
The better you understand Dyne Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dyne Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dyne Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Dyne Therapeutics Competition Performance Charts
Five steps to successful analysis of Dyne Therapeutics Competition
Dyne Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dyne Therapeutics in relation to its competition. Dyne Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Dyne Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dyne Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dyne Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Dyne Therapeutics position
In addition to having Dyne Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Treasury ETFs Thematic Idea Now
Treasury ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 131 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Dyne Therapeutics Correlation with its peers. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.